Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.
The insulin-like growth factor-I receptor (IGF-IR) was first cloned in 1986. Since then, intense work has defined classic phosphorelays activated via the IGF-IR, which regulate cell proliferation, apoptosis, motility, and fate. The understanding of the roles of hormones in cancer and the growth hormone-IGF-IGF-binding protein axis specifically has yield to a second wave of development: the design of specific inhibitors that interrupt the signaling associated with this axis. The ability to manipulate these pathways holds not only significant therapeutic implications but also increase the chance of deeper insight about the role of the axis in carcinogenesis and metastasis. Nowadays, >25 molecules with the same goal are at different stages of development. Here, we review the clinical and preclinical experience with the two most-investigated strategies, tyrosine kinase inhibitors and monoclonal antibodies, and the advantages and disadvantages of each strategy, as well as other alternatives and possible drug combinations. We also review the biomarkers explored in the first clinical trials, the strategies that have been explored thus far, and the clinical trials that are going to explore their role in cancer treatment.
Rodon
Jordi
J
Investigational Cancer Therapeutics, University of Texas M. D. Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA. jrodonahnert@gmail.com
DeSantos
Victoria
V
Ferry
Robert Jean
RJ
Kurzrock
Razelle
R
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D017526:Receptor, IGF Type 1
Exp Biol Med (Maywood). 2007 Jan;232(1):70-80
17202587
Lab Invest. 2002 Oct;82(10):1377-89
12379772
Biochem Pharmacol. 2006 May 14;71(10):1435-48
16530734
Cancer Gene Ther. 2005 Jan;12(1):90-100
15499378
Breast Cancer Res Treat. 2005 Nov;94(1):37-46
16142439
Anticancer Drugs. 2007 Mar;18(3):237-44
17264754
Cancer Biol Ther. 2005 Jul;4(7):687-93
16082179
JAMA. 2007 Jul 18;298(3):289-98
17635889
Breast Cancer Res Treat. 1997 Sep;45(2):141-7
9342439
Br J Cancer. 2006 Feb 27;94(4):465-8
16450000
Nat Rev Drug Discov. 2006 Oct;5(10):835-44
17016424
Cancer Res. 2005 Dec 1;65(23):11118-28
16322262
Mol Cancer Ther. 2007 Apr;6(4):1175-9
17431100
Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s
17875788
Br J Cancer. 2006 Nov 6;95(9):1148-54
17031397
World J Gastroenterol. 2007 Jun 21;13(23):3164-70
17589893
Clin Cancer Res. 2005 Apr 15;11(8):3065-74
15837762
Cancer Res. 2002 Jan 1;62(1):200-7
11782378
Cancer Res. 2005 May 1;65(9):3868-76
15867386
Clin Cancer Res. 2005 Mar 1;11(5):2063-73
15756033
Nat Clin Pract Oncol. 2006 May;3(5):269-80
16683005
J Clin Endocrinol Metab. 2007 Dec;92(12):4529-35
17986643
Anticancer Res. 2006 Sep-Oct;26(5B):3693-700
17094387
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40
16740780
Endocr Rev. 2007 Feb;28(1):20-47
16931767
World J Gastroenterol. 2006 Sep 21;12(35):5635-43
17007015
Cancer Res. 2006 Feb 15;66(4):2391-402
16489046
J Clin Endocrinol Metab. 1998 May;83(5):1713-20
9589681
Oncogene. 2001 Aug 16;20(36):4942-50
11526479
Mol Cancer Res. 2007 Jun;5(6):523-30
17579114
J Biol Chem. 2003 Feb 28;278(9):6702-9
12493743
Cancer Lett. 2007 Apr 18;248(2):269-79
16996205
Clin Exp Metastasis. 2008;25(6):685-93
18236164
Cancer Immunol Immunother. 2007 Mar;56(3):343-57
16832681
Drug Discov Today. 2005 Aug 1;10(15):1041-7
16055020
Clin Cancer Res. 2005 Feb 15;11(4):1563-71
15746061
Clin Cancer Res. 2001 Jun;7(6):1790-7
11410521
J Biol Chem. 2005 May 20;280(20):19665-72
15757893
Clin Cancer Res. 2007 Oct 1;13(19):5834-40
17908976
Clin Cancer Res. 2007 Feb 15;13(4):1322-30
17317844
Cancer Res. 2006 Jan 1;66(1):362-71
16397250
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6153-60
17062692
Cancer Res. 2005 Oct 15;65(20):9455-62
16230409
Integr Cancer Ther. 2003 Dec;2(4):315-29
14713323
Am J Med Sci. 2002 Mar;323(3):140-5
11908858
Cancer Cell. 2004 Mar;5(3):231-9
15050915
Int J Cancer. 2005 Jan 10;113(2):316-28
15386423
Cancer Res. 2004 Sep 1;64(17):6252-8
15342412
J Endocrinol Invest. 1996 May;19(5):324-33
8796343
Cancer Res. 2003 Aug 15;63(16):5073-83
12941837
Anticancer Res. 1995 Nov-Dec;15(6B):2687-90
8669848
Breast Cancer Res Treat. 2006 Aug;98(3):315-27
16541323
Cancer Res. 1998 Jul 15;58(14):3021-7
9679966
Clin Cancer Res. 2007 Feb 1;13(3):1000-9
17289896
Horm Res. 1994;41 Suppl 2:56-64; discussion 65
8088705
Recent Results Cancer Res. 2007;172:59-76
17607936
Cancer Cell. 2004 Mar;5(3):221-30
15050914
Proc Soc Exp Biol Med. 1998 Feb;217(2):143-52
9452137
Cancer. 2001 Dec 1;92(11):2941-7
11753970
J Biol Chem. 1986 Dec 15;261(35):16727-31
2946689
J Clin Endocrinol Metab. 2000 Sep;85(9):3036-42
10999782
Cancer Res. 1997 Aug 1;57(15):3079-83
9242428
Crit Rev Oncol Hematol. 2006 Apr;58(1):1-14
16388966
Mol Cancer Ther. 2007 Feb;6(2):667-74
17308062
Biochem Biophys Res Commun. 1994 Aug 30;203(1):253-9
8074663
Cancer Res. 1992 Sep 15;52(18):4973-8
1325289
Nat Rev Cancer. 2006 Sep;6(9):714-27
16929325
Cancer Res. 2006 Feb 1;66(3):1873-8
16452250
Clin Cancer Res. 1999 Jul;5(7):1935-44
10430101
Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):33-43
18084344
Eur J Cancer. 2007 May;43(8):1318-27
17451939
Clin Cancer Res. 2007 Jun 15;13(12):3611-6
17575225
Growth Horm IGF Res. 2001 Jun;11 Suppl A:S121-3
11527083
Cancer Res. 2007 Feb 1;67(3):1155-62
17283150
Cancer. 2002 Jan 15;94(2):299-304
11900215
Horm Res. 1999;51(2):53-67
10352394
Cancer Res. 2003 Dec 15;63(24):8912-21
14695208
Neuroendocrinology. 2007;85(1):54-60
17310129
Semin Oncol. 2006 Aug;33(4):392-406
16890795
Eur J Nutr. 2005 Feb;44(1):18-25
15309460
Mol Cancer Ther. 2006 Jan;5(1):114-20
16432169
Cancer. 1999 Mar 15;85(6):1284-92
10189133
Nat Rev Drug Discov. 2004 May;3(5):391-400
15136787